Genmab AS (FRA:GE91) Margin of Safety % (DCF Earnings Based): 57.23% (As of Jun. 24, 2026)


FRA:GE91 Genmab AS FRA:GE91
93 GF Score
Price €21.80
GF Value €29.03
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Genmab AS Margin of Safety % (DCF Earnings Based)?

Genmab AS FRA:GE91 +0.93% 93 Margin of Safety % (DCF Earnings Based) is 57.23% as of Jun. 24, 2026. GuruFocus rates FRA:GE91 with a GF Score™ of 93/100 and a GF Value™ of €29.03 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

As of today (2026-06-24), Genmab AS's Predictability Rank is 3-Stars. Genmab AS's intrinsic value calculated from the Discounted Earnings model is €50.97 and current share price is €21.80. Consequently,

Genmab AS's Margin of Safety % (DCF Earnings Based) using Discounted Earnings model is 57.23%.

FRA:GE91 vs VRTX, REGN, ALNY: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Genmab AS's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genmab AS Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab AS's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Genmab AS's Margin of Safety % (DCF Earnings Based) falls into.


FRA:GE91
93GF Score
Genmab AS FRA:GE91
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genmab AS Margin of Safety % (DCF Earnings Based) Calculation

Genmab AS's Margin of Safety % (DCF Earnings Based) for today is calculated as

Margin of Safety % (DCF Earnings Based)=(Intrinsic Value: DCF (Earnings Based)-Current Price)/Intrinsic Value: DCF (Earnings Based)
=(50.97-21.80)/50.97
=57.23 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The intrinsic value is calculated from the Discounted Earnings model with default parameters. The calculation method is the same as Discounted Cash Flow model except earnings are used in the calculation instead of free cash flow.

What does a Margin of Safety % (DCF Earnings Based) of 57.23% mean?
Genmab AS (FRA:GE91) has a Margin of Safety % (DCF Earnings Based) of 57.23% as of Jun. 24, 2026. Margin of Safety % (DCF Earnings Based) is the percent difference between the current price and the intrinsic DCF Earnings price. View historical data on Genmab AS.
Is Genmab AS's Margin of Safety % (DCF Earnings Based) too high?
Genmab AS's current Margin of Safety % (DCF Earnings Based) is 57.23%. Overall, Genmab AS has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genmab AS's Margin of Safety % (DCF Earnings Based) compare to VRTX and REGN?
Genmab AS's Margin of Safety % (DCF Earnings Based) of 57.23% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Margin of Safety % (DCF Earnings Based) for a Biotechnology company?
A good Margin of Safety % (DCF Earnings Based) depends on the Biotechnology industry context. However, Margin of Safety % (DCF Earnings Based) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Margin of Safety % (DCF Earnings Based) mean?
A high Margin of Safety % (DCF Earnings Based) can signal that a stock is expensive relative to its fundamentals. Margin of Safety % (DCF Earnings Based) is the percent difference between the current price and the intrinsic DCF Earnings price. View historical data on Genmab AS. Genmab AS's current Margin of Safety % (DCF Earnings Based) is 57.23%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genmab AS stock overvalued right now?
Based on GuruFocus' analysis, Genmab AS (FRA:GE91) is currently considered Modestly Undervalued. The stock's GF Value™ is €29.03, compared to a current price of €21.80 — trading 24.9% below its estimated fair value. The current Margin of Safety % (DCF Earnings Based) is 57.23%. Genmab AS's overall GF Score™ is 93/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Margin of Safety % (DCF Earnings Based) calculated?
Margin of Safety % (DCF Earnings Based) is calculated from a company's financial statements. For Genmab AS (FRA:GE91), the current Margin of Safety % (DCF Earnings Based) is 57.23% as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genmab AS (FRA:GE91) Overvalued in 2026?

Based on GuruFocus' analysis, Genmab AS stock appears to be undervalued. The current stock price of €21.80 is trading 24.9% below its estimated GF Value™ of €29.03. GuruFocus considers Genmab AS to be Modestly Undervalued.

Key valuation signals for FRA:GE91:

  • Margin of Safety % (DCF Earnings Based): 57.23%
  • GF Value™: €29.03 vs. price of €21.80 (24.9% below fair value)
  • GF Score™: 93/100 with 5 warning signs

No single metric tells the full story. See the FRA:GE91 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Genmab AS Business Description

Address Carl Jacobsens Vej 30, Valby, DNK, 2500
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
93GF Score

Get the complete analysis for FRA:GE91

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€21.80
Price
€29.03
GF Value